Current Gene Therapy

Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard


Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy

Author(s): William S.M. Wold and Karoly Toth

Affiliation: Saint Louis University School of Medicine, Department of Molecular Microbiology & Immunology, 1100 S. Grand Blvd., St. Louis, MO 63104. USA.


Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Such vectors are used for gene therapy, as vaccines, and for cancer therapy. Replication-competent (oncolytic) vectors are employed for cancer gene therapy. Oncolytic vectors are engineered to replicate preferentially in cancer cells and to destroy cancer cells through the natural process of lytic virus replication. Many clinical trials indicate that replication-defective and replication-competent adenovirus vectors are safe and have therapeutic activity.

Keywords: Adenovirus, replication-defective, oncolytic, cancer gene therapy, vaccines, safe and well-tolerated.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [421 - 433]
Pages: 13
DOI: 10.2174/1566523213666131125095046